Compare PGY & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | MDXG |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | 511 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 530.2M |
| IPO Year | N/A | 2007 |
| Metric | PGY | MDXG |
|---|---|---|
| Price | $12.73 | $3.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $34.50 | $9.00 |
| AVG Volume (30 Days) | ★ 3.5M | 1.7M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | $14.27 | N/A |
| Revenue Next Year | $14.39 | $13.02 |
| P/E Ratio | $13.54 | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $10.40 | $3.03 |
| 52 Week High | $44.99 | $7.99 |
| Indicator | PGY | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 49.42 |
| Support Level | $10.78 | $3.45 |
| Resistance Level | $15.57 | $7.39 |
| Average True Range (ATR) | 0.89 | 0.12 |
| MACD | -0.21 | 0.04 |
| Stochastic Oscillator | 12.12 | 51.43 |
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.